Navigation Links
Assay Designs(TM) Announces Collaboration with Medical University of South Carolina (MUSC)
Date:5/5/2008

ANN ARBOR, Mich., May 5 /PRNewswire/ -- Assay Designs, Inc., a leading provider of immunoassay kits, antibodies, and reagents to the life sciences and translational research markets, announced a collaboration on a joint antibody research project with the Medical University of South Carolina and Dr. Jennifer Isaacs' laboratory. Under the terms of this agreement, Assay Designs will provide anti-Heat shock protein 90 (Hsp90) antibody for both cell-based and animal-based work.

This collaboration agreement will allow Dr. Isaacs to move forward with research investigating the role of Hsp90 in the progression of many cancers. "I am excited about the prospect of utilizing this antibody to target the Hsp90 chaperone and to potentially curtail the metastatic properties of some cancers. Moreover, we now have a new tool to explore the role of cell surface localized Hsp90 protein in cancer progression. Since this antibody is well-tolerated in animals, this approach paves the way for a promising therapeutic strategy, " stated Dr. Isaacs.

"As the leader in heat shock proteins (HSPs) and chaperones, collaborations such as this provide valuable insight for our new product development efforts," stated Dan Calvo, Assay Designs' President and CEO. "Supporting the validation of new and novel test protocols enhances the value and flexibility of our broad HSP product portfolio."

About Assay Designs, Inc.

Based in Ann Arbor, MI, Assay Designs develops, manufactures and markets immunoassay (ELISA) kits, antibodies, and proteins that are used for life sciences research. The company markets these products under the "Assay Designs" and "Stressgen" brand names. Researchers use Assay Designs products to detect and quantify molecules that are important biomarkers of inflammation, heat shock, cell signaling, and oxidative stress.

About Isaacs Lab.

A long-term research goal of the Isaacs Lab is to better understand the role of Hsp90 in tumor progression to ultimately optimize the use and potency of Hsp90 inhibitors in the clinic. In particular, the lab investigates how Hsp90 contributes to angiogenic processes and cell migration, representing two fundamental and universal aspects of cancer progression. Specifically, the tumor-promoting roles of Hsp90 are being assessed in various invasive cancers, such as prostate, renal cell carcinoma (RCC), and the deadly disease glioblastoma (GBM). Clinically relevant orthotopic models of RCC and GBM are being used and newer forms of Hsp90 antagonists are being evaluated. In collaboration with other groups, there is also interest in identifying combination treatments most effective against these cancers.


'/>"/>
SOURCE Assay Designs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics
2. Genetic Engineering & Biotechnology News reports on growing use of cell-based assays
3. Genetic Engineering & Biotechnology News Reports on Growing Use of Cell-Based Assays
4. Cellix Ltd. Launches VenaEC Biochip for Flow-based Cell-adhesion Assays
5. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
6. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
7. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
8. Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform
9. A New, Unique and Unrivalled Rat/Mouse PINP Assay for Pharmaceutical, Clinical and Academic Research Organizations.
10. Study Reaffirms Superiority of Trofile(TM) Assay
11. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 NanoStruck ... (OTCPink: NSKQB) ( Frankfurt : 8NSK) ... Pressemitteilung vom 13. August 2015 die Genehmigung von ... um zusätzliche 200.000.000 Einheiten auf 400.000.000 Einheiten zu ... bringen. Davon wurden 157.900.000 Einheiten mit dem ersten ...
(Date:4/27/2016)... ... 2016 , ... PathSensors, Inc., a leading environmental testing company, ... assist PathSensors in expanding the use of the company’s CANARY® technology in the ... for the detection of harmful pathogens, including a number of bacteria, viruses, toxins, ...
(Date:4/27/2016)... 27, 2016 MedDay, a biotechnology company ... the appointment of Catherine Moukheibir as Chairman of its Board ... Jean Jacques Garaud , who contributed to the rapid ... immediately. Catherine started her career in strategy consulting ... London .  She held C-Suite level roles ...
(Date:4/26/2016)... ... 2016 , ... The European Patent Office (EPO) today announced that ... for the European Inventor Award 2016 in the category "Non-European countries." The winners of ... ceremony in Lisbon on June 9th. , The human capacity to walk with fluidity ...
Breaking Biology Technology:
(Date:3/14/2016)... Allemagne, March 14, 2016 ... - --> - Renvoi : image disponible ... --> --> DERMALOG, ... fournit de nouveaux lecteurs d,empreintes digitales pour l,enregistrement ... DERMALOG sera utilisé pour produire des cartes d,identité ...
(Date:3/10/2016)... --  Unisys Corporation (NYSE: UIS ) today announced ... testing its biometric identity solution at the Otay Mesa border ... identify certain non-U.S. citizens leaving the country. ... determine the efficiency and accuracy of using biometric technologies in ... until May 2016. --> the United States ...
(Date:3/8/2016)... 2016   Valencell , the leading innovator ... has secured $11M in Series D financing. The ... venture fund being launched by UAE-based financial services ... investors TDF Ventures and WSJ Joshua Fund. Valencell ... triple-digit growth and accelerate its pioneering innovation in ...
Breaking Biology News(10 mins):